Vlad Andrei Cianga

Dr. Vlad Andrei Cianga

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
TATeodora Alexa-Stratulat
Teodora Alexa-Stratulat
MPMariana Pavel-Tanasa
Mariana Pavel-Tanasa
VCVlad Andrei Cianga
Vlad Andrei Cianga
SASabina Antonela Antoniu
Sabina Antonela Antoniu
: Lung cancer and mainly non-small cell lung cancer (NSCLC) still remain a prevalent malignancy worldwide despite sustained screening approaches. Furthermore, a significant proportion of the cases are diagnosed at advanced stages when conservative therapy is often unsuccessful. Cell senescence is an endogenous antitumor weapon but when it is upregulated exerts opposite activities favoring tumor metastasizing and poor response to therapy. However, little is known about this dangerous relationship between cell senescence and NSCLC outcome or on potential approaches to mitigate its unfavorable consequences. : We discuss cell senescence focusing on immune senescence its cell and humoral effectors (namely immune senescence associated secretory phenotype-iSASP), its impact on NSCLC outcome and its biomarkers. Senotherapeutics as mitigating approaches are also considered based on the availability of experimental data pertinent to NSCLC. : Characterization of NSCLC subsets in which immune senescence is a risk factor for poor prognosis and poor therapeutic response might be very helpful in supporting the addition of senotherapeutics to conventional cancer therapy. This approach has the potential to improve disease outcome but more studies in this area are necessary.

10 December 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
IAIon Antohe
Ion Antohe
ATAmalia Titieanu
Amalia Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
CMCosmin Minciună
Cosmin Minciună
CDCătălin Dănăilă
Cătălin Dănăilă
ADAngela Dăscălescu
Angela Dăscălescu
Introduction: The management of adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a significant challenge, with patients presenting particularly poor historical outcomes. Novel immunotherapies, such as Blinatumomab and Inotuzumab, have revived the therapeutic landscape of R/R B-ALL, but their optimal sequencing, toxicity management, and post-transplant integration remain unclear, particularly in real-world, resource-limited settings. Methods: We conducted a retrospective analysis of 33 adult patients with R/R B-ALL treated between 2019 and 2023 at two major oncology centers in Romania. Results: Blinatumomab and Inotuzumab achieved complete remission rates of 47.6% and 90%, respectively, with measurable residual disease negativity in over 60% of responders. Inotuzumab was more effective in early relapses and cases with high disease burden, while Blinatumomab showed benefit in later relapses and post-transplant settings. Eleven patients were successfully bridged to allogeneic stem cell transplant, and four were treated for post-transplant relapse, demonstrating the feasibility of immunotherapy in both contexts. Sequential monoclonal antibody use yielded poor survival unless used as a bridge to curative therapy. Conclusion: Our findings emphasize the need for individualized treatment selection, rational immunotherapy sequencing, and the development of predictive biomarkers to optimize outcomes and minimize toxicity. Further studies are needed to refine therapeutic algorithms and define such prognostic biomarkers, particularly in underfunded healthcare systems.

19 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CMCosmin Minciuna
Cosmin Minciuna
DMDorina Adelina Minciuna
Dorina Adelina Minciuna
ADAngela Dascalescu
Angela Dascalescu
ATAmalia Titieanu
Amalia Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
LMLucian Miron
Lucian Miron
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous malignancy with variable outcomes. Accurate risk prediction at diagnosis remains essential to guide treatment and follow-up strategies. In this retrospective study we aimed to assess the performance of multiple modeling approaches to predict death by 26 months of follow-up in patients with DLBCL using data available in the diagnostic stage. Methods: In this study we included 412 patients with DLBCL who were evaluated, treated, and followed-up at the Regional Institute of Oncology in Iasi, Romania, between 2015 and 2023. Clinical and paraclinical data determined at baseline examination was used to train and test six machine learning models (logistic regression, random forest—RF, support vector machine with a radial-basis kernel—SVM-RBF, multilayer perceptron neural network—MLP, random survival forest—RSF, and extreme gradient boosting—XGBoost) and to compare their performance to the Cox proportional hazards model. Results: Among the models, RF achieved the highest discrimination (AUC = 0.9060), with balanced performance (accuracy = 0.833; F1 = 0.902), followed by XGBoost (AUC = 0.8335) and MLP (AUC = 0.7861; accuracy = 0.849). RF and logistic regression demonstrated the best calibration (Brier = 0.360 and 0.377). The Cox model achieved moderate discrimination (time-dependent AUC = 0.5561; C-index = 0.55). Conclusions: Our findings align with contemporary reports showing that machine learning frameworks can outperform classical prediction approaches.

30 December 2025 in Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi
Verified
Journal Article
Open access
PDF file
IAI. Antohe
I. Antohe
VCVlad Andrei Cianga
Vlad Andrei Cianga
CMC. Minciună
C. Minciună
ATAmali Titieanu
Amali Titieanu
DFDiana-Marina Fortoeș
Diana-Marina Fortoeș
ADAngela Dăscălescu
Angela Dăscălescu
Allogeneic stem cell transplantation (allo-SCT) remains the only curative treatment option for acute myeloid leukemia (AML) patients. We present the outcomes of 59 AML patients who underwent allo-SCT at our center. Materials and methods: We retrospectively analyzed patients transplanted between 2019 and 2024. Baseline characteristics included age, sex, ELN 2022 risk, disease status at transplant (CR1, CR2, active disease), donor type, GVHD prophylaxis. Outcomes evaluated were engraftment, acute and chronic GVHD, cumulative incidence of relapse (CIR), non-relapse mortality (NRM), overall survival (OS), disease-free survival (DFS). Survival was estimated by the Kaplan-Meier method. Results: The median age was 44 years. 84.7% of patients were transplanted in CR1. Donors included: matched sibling 42.4%, unrelated 49.2%, and haploidentical 8.5%. Incidence of grade II-IV acute GVHD was 16.9%, and chronic GVHD 25.4%. At a median follow-up of 26 months (95% CI: 32-44), OS and DFS were not reached. Patients transplanted in CR1 showed the best outcomes (mean OS 88.7 months; 2-year DFS: 74%), while CR2 patients had inferior results (mean OS 33.5 months; 2-year DFS: 40-45%). Differences were significant (OS p=0.004; DFS p=0.007). Measurable residual disease at day+90 was the single most robust factor for predicting outcome in both univariate and multivariable analysis. Conclusions: Our single-center experience confirms that allo-SCT is feasible and effective in AML, with outcomes comparable to international reports. The disease status at the moment of transplantation and measurable residual disease remain the most powerful prognostic factors to identify patients at high risk of relapse.

18 August 2023 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
ATAmalia-Andrea Titieanu
Amalia-Andrea Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
CDCatalin Doru Danaila
Catalin Doru Danaila
MDMIHAIELA LOREDANA DRAGOȘ
MIHAIELA LOREDANA DRAGOȘ
ICIVANOV IULIU CRISTIAN
IVANOV IULIU CRISTIAN
ADAngela Dascalescu
Angela Dascalescu

24 March 2025 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
DFDiana-Marina Fortoes
Diana-Marina Fortoes
ENElena Nicorici
Elena Nicorici
CMCosmin Minciuna
Cosmin Minciuna
VCVlad Andrei Cianga
Vlad Andrei Cianga
RTRamona Timofte
Ramona Timofte
CDCatalin Danaila
Catalin Danaila
Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2017–2021 (immunotherapy), with survival endpoints (OS, PFS, EFS1-3) analyzed by Kaplan–Meier and log-rank tests. Results: The immunotherapy group achieved a higher overall response rate (80% vs. 36.7%, p=0.001), longer median OS (47 vs. 30 months) and superior EFS1–3 (33 vs. 16 months, 32.5 vs. 8 months, 38 vs. 23 months; all p 0.05) compared to historical controls. Conclusion: Incorporation of brentuximab vedotin and PD-1 blockade before and after autologous SCT significantly improves response and survival outcomes in relapsed/refractory Hodgkin lymphoma, supporting earlier use of these agents in salvage and frontline settings.